Stay updated with breaking news from Fotivda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(2) NEW YORK CITY (dpa-AFX) - AVEO Oncology (AVEO) said Friday that it reached a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate Fotivda or tivozanib in combination with Opdivo or nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, in the pivotal Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma or RCC following prior immunotherapy exposure. Fotivda is an oral, next-generation vascular endothelial growth factor tyrosine kinase inhibitor approved for the treatment of adult patients with relapsed or refractory advanced RCC following two or more prior systemic therapies. It is expected that the trial will enroll about 326 patients with advanced RCC who have progressed following prior immunotherapy treatment.